title: Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective.
abstract: OBJECTIVE
  The introduction of ready-to-use lanreotide Autogel has presented the possibility of patients receiving their acromegaly treatment at home. The objective of this study was to assess the ability of patients (or their partners) to administer repeat, unsupervised, injections of lanreotide Autogel without compromising efficacy or safety.
  
  
  METHODS
  Multicentre (10 UK regional endocrine centres), open-label, nonrandomised, controlled study. Patients elected either to receive/administer unsupervised home injections after injection technique training (Test group) or continued to receive injections from a healthcare professional (Control group). Patients received monthly injections of lanreotide Autogel at their established dose. Effects were monitored for up to 40 weeks.
  
  
  METHODS
  Thirty patients (15 per treatment group) with acromegaly treated with a stable dose of lanreotide Autogel (60, 90 or 120 mg) for > or = 4 months before screening. Measurements The main outcome measure was the proportion of patients/partners who successfully administered injections throughout the study.
  
  
  RESULTS
  All Test group patients/partners qualified to administer injections. Fourteen of 15 patients fulfilled all criteria for successful administration of unsupervised injections (95% confidence interval, 70%-99%). Fourteen of 15 Test and 14/15 Control patients maintained growth hormone and IGF-1 control. Local injection tolerability was good for both treatment groups, and safety profiles were similar. All Test group patients continued with unsupervised injections after the study.
  
  
  CONCLUSIONS
  Patients with acromegaly or their partners were able to administer lanreotide Autogel injections with no detrimental effect on efficacy and safety; therefore, unsupervised home injections are a viable alternative to healthcare professional injections for suitably motivated patients.
authors: Department of Endocrinology, Aberdeen Royal Infirmary, Foresterhill, Aberdeen, UK. j.s.bevan@arh.grampian.scot.nhs.uk
authors: J S
authors: JS
authors: Bevan
authors: J
authors: J
authors: Newell-Price
authors: J A H
authors: JA
authors: Wass
authors: S L
authors: SL
authors: Atkin
authors: P M
authors: PM
authors: Bouloux
authors: J
authors: J
authors: Chapman
authors: J R E
authors: JR
authors: Davis
authors: T A
authors: TA
authors: Howlett
authors: H S
authors: HS
authors: Randeva
authors: P M
authors: PM
authors: Stewart
authors: A
authors: A
authors: Viswanath
mesh_terms: D000172:Acromegaly / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006701:Home Nursing; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000008:administration & dosage*; D012648:Self Care; D013004:Somatostatin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D016896:Treatment Outcome
chemical_list: D010456:Peptides, Cyclic; C060347:lanreotide; D013004:Somatostatin